Neuland Laboratories · NSE: NEULANDLAB · BSE: 524558
Q4 FY25 results · Jan–Mar 2025
Neuland Laboratories reported revenue from operations of ₹328.36 crore (down 14.7% from Q4 FY24) and net profit of ₹27.81 crore (down 58.8% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 328.36 | 385.01 | −14.7% | 398.03 | −17.5% |
| Other income | 7.46 | 5.36 | +39.3% | 3.91 | +91.1% |
| Total income | 335.82 | 390.37 | −14.0% | 401.94 | −16.4% |
| Profit before tax | 39.30 | 92.20 | −57.4% | 127.76 | −69.2% |
| Net profit for the period | 27.81 | 67.56 | −58.8% | 101.59 | −72.6% |
| EPS, basic (₹) | 21.67 | 52.66 | −58.8% | 79.18 | −72.6% |
| Net margin (%) | 8.5 | 17.5 | 25.5 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 328.36 | 385.01 | −14.7% | 398.03 | −17.5% |
| Other income | 7.46 | 5.36 | +39.3% | 3.91 | +91.1% |
| Total income | 335.82 | 390.37 | −14.0% | 401.94 | −16.4% |
| Profit before tax | 38.98 | 92.08 | −57.7% | 127.54 | −69.4% |
| Net profit for the period | 27.73 | 67.61 | −59.0% | 101.39 | −72.6% |
| EPS, basic (₹) | 21.62 | 52.70 | −59.0% | 79.03 | −72.6% |
| Net margin (%) | 8.4 | 17.6 | 25.5 |
Consolidated
- Filed with BSE
- 15 May 2025, 19:01 IST
- Board meeting
- 15 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 15 May 2025, 19:01 IST
- Board meeting
- 15 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE